BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33303972)

  • 21. Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.
    Wu Z; Liu Z; Jiang X; Mi Z; Meng M; Wang H; Zhao J; Zheng B; Yuan Z
    J Exp Clin Cancer Res; 2019 Aug; 38(1):341. PubMed ID: 31387622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
    Wang M; Li P; Wan R; Liu X
    Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
    Al-Saad S; Richardsen E; Kilvaer TK; Donnem T; Andersen S; Khanehkenari M; Bremnes RM; Busund LT
    PLoS One; 2017; 12(7):e0181527. PubMed ID: 28742836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma.
    Shiran I; Heller E; Jessel S; Kamer I; Daniel-Meshulam I; Navon R; Urban D; Onn A; Bar J
    Clin Lung Cancer; 2017 May; 18(3):316-323.e1. PubMed ID: 28237243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
    Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
    Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA
    Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
    Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients.
    Kuang BH; Wen XZ; Ding Y; Peng RQ; Cai PQ; Zhang MQ; Jiang F; Zhang XS; Zhang X
    Med Oncol; 2013 Jun; 30(2):536. PubMed ID: 23494670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FHIT, EGFR, and MSH2: possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in Egyptian patients.
    Younes SF; Aiad HA; Asaad NY; Kandil MA; Natkunam Y; Mokhtar NM
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):275-83. PubMed ID: 24185125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer.
    Cui R; Meng W; Sun HL; Kim T; Ye Z; Fassan M; Jeon YJ; Li B; Vicentini C; Peng Y; Lee TJ; Luo Z; Liu L; Xu D; Tili E; Jin V; Middleton J; Chakravarti A; Lautenschlaeger T; Croce CM
    Proc Natl Acad Sci U S A; 2015 Aug; 112(31):E4288-97. PubMed ID: 26187928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer.
    Sun L; Yuan H; Burnett J; Gasparyan M; Zhang Y; Zhang F; Yang Z; Ran Y; Sun D
    Int J Med Sci; 2019; 16(1):68-74. PubMed ID: 30662330
    [No Abstract]   [Full Text] [Related]  

  • 40. LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.
    Yang J; Du YM; Li B
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):660-669. PubMed ID: 30720174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.